As to tumor heterogeneity, the deep learning score of EGFR mutation provides a non-invasive method for identifying NSCLC patients sensitive to EGFR tyrosine kinase inhibitors or immune checkpoint inhibitors treatments (19). This evidence concerns the gene EGFR and neoplasm.